AURORA CANNABIS INC (ACB.CA) Stock Fundamental Analysis
TSX:ACB - Toronto Stock Exchange - CA05156X8504 - Common Stock - Currency: CAD
Taking everything into account, ACB scores 4 out of 10 in our fundamental rating. ACB was compared to 35 industry peers in the Pharmaceuticals industry. The financial health of ACB is average, but there are quite some concerns on its profitability. ACB is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year ACB was profitable.
ACB had a negative operating cash flow in the past year.
In the past 5 years ACB always reported negative net income.
ACB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of 1.44%, ACB is doing good in the industry, outperforming 77.14% of the companies in the same industry.
ACB has a Return On Equity of 2.18%. This is in the better half of the industry: ACB outperforms 74.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.44% | ||
| ROE | 2.18% | ||
| ROIC | N/A |
ROA(3y)-64.28%
ROA(5y)-63.23%
ROE(3y)-101.76%
ROE(5y)-92.93%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ACB (3.90%) is better than 80.00% of its industry peers.
Looking at the Gross Margin, with a value of 3.82%, ACB is doing worse than 77.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 3.9% | ||
| GM | 3.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACB has more shares outstanding than it did 1 year ago.
ACB has more shares outstanding than it did 5 years ago.
ACB has a better debt/assets ratio than last year.
2.2 Solvency
ACB has an Altman-Z score of -8.76. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.76, ACB is doing worse than 82.86% of the companies in the same industry.
ACB has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
ACB's Debt to Equity ratio of 0.07 is fine compared to the rest of the industry. ACB outperforms 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.76 |
ROIC/WACCN/A
WACC8.7%
2.3 Liquidity
ACB has a Current Ratio of 3.30. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
ACB has a better Current ratio (3.30) than 85.71% of its industry peers.
ACB has a Quick Ratio of 1.60. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.60, ACB is doing good in the industry, outperforming 65.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.3 | ||
| Quick Ratio | 1.6 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 113.32% over the past year.
Looking at the last year, ACB shows a quite strong growth in Revenue. The Revenue has grown by 19.92% in the last year.
ACB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.40% yearly.
EPS 1Y (TTM)113.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%216%
Revenue 1Y (TTM)19.92%
Revenue growth 3Y-1.04%
Revenue growth 5Y37.4%
Sales Q2Q%36.91%
3.2 Future
Based on estimates for the next years, ACB will show a very strong growth in Earnings Per Share. The EPS will grow by 30.94% on average per year.
Based on estimates for the next years, ACB will show a quite strong growth in Revenue. The Revenue will grow by 13.38% on average per year.
EPS Next Y84.56%
EPS Next 2Y55.4%
EPS Next 3Y39.53%
EPS Next 5Y30.94%
Revenue Next Year25.33%
Revenue Next 2Y18.21%
Revenue Next 3Y14.48%
Revenue Next 5Y13.38%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 35.35, the valuation of ACB can be described as expensive.
Based on the Price/Earnings ratio, ACB is valued a bit cheaper than the industry average as 71.43% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.59. ACB is valued slightly more expensive when compared to this.
Based on the Price/Forward Earnings ratio of 23.96, the valuation of ACB can be described as rather expensive.
Based on the Price/Forward Earnings ratio, ACB is valued a bit cheaper than 77.14% of the companies in the same industry.
ACB's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.39.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.35 | ||
| Fwd PE | 23.96 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ACB's earnings are expected to grow with 39.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.42
PEG (5Y)N/A
EPS Next 2Y55.4%
EPS Next 3Y39.53%
5. Dividend
5.1 Amount
ACB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:ACB (6/10/2025, 7:00:00 PM)
8.13
+0.32 (+4.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners13.84%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap446.01M
Analysts74
Price Target10.51 (29.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2191.63%
Min EPS beat(2)-110.8%
Max EPS beat(2)4494.06%
EPS beat(4)2
Avg EPS beat(4)1134.64%
Min EPS beat(4)-110.8%
Max EPS beat(4)4494.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.22%
Min Revenue beat(2)13.79%
Max Revenue beat(2)14.66%
Revenue beat(4)3
Avg Revenue beat(4)7.53%
Min Revenue beat(4)-5.3%
Max Revenue beat(4)14.66%
Revenue beat(8)6
Avg Revenue beat(8)5.79%
Revenue beat(12)6
Avg Revenue beat(12)2.25%
Revenue beat(16)8
Avg Revenue beat(16)1.88%
PT rev (1m)0%
PT rev (3m)3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)52.38%
EPS NY rev (1m)0%
EPS NY rev (3m)88.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.35 | ||
| Fwd PE | 23.96 | ||
| P/S | 1.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.78 | ||
| P/tB | 0.92 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.23
EY2.83%
EPS(NY)0.34
Fwd EY4.17%
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS5.84
BVpS10.44
TBVpS8.86
PEG (NY)0.42
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.44% | ||
| ROE | 2.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 3.9% | ||
| GM | 3.82% | ||
| FCFM | N/A |
ROA(3y)-64.28%
ROA(5y)-63.23%
ROE(3y)-101.76%
ROE(5y)-92.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 86.17% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.3 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z | -8.76 |
F-Score6
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)46.6%
Cap/Depr(5y)183.64%
Cap/Sales(3y)14.16%
Cap/Sales(5y)67.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)113.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%216%
EPS Next Y84.56%
EPS Next 2Y55.4%
EPS Next 3Y39.53%
EPS Next 5Y30.94%
Revenue 1Y (TTM)19.92%
Revenue growth 3Y-1.04%
Revenue growth 5Y37.4%
Sales Q2Q%36.91%
Revenue Next Year25.33%
Revenue Next 2Y18.21%
Revenue Next 3Y14.48%
Revenue Next 5Y13.38%
EBIT growth 1Y7.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year209.18%
EBIT Next 3Y52.39%
EBIT Next 5Y31.49%
FCF growth 1Y80.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.36%
OCF growth 3YN/A
OCF growth 5YN/A